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Fundamentally, the identification of causes and con-
tributors of disease represents the first step in an
etiology-based understanding of disease. This, in turn,
is a required step in the development of therapeutics
targeting the underlying disease process. Parkinson’s
disease (PD) is believed to be a complex disorder, with
disease liability driven in part by genetics. Current heri-
tability estimates suggest that common genetic variabil-
ity contributes 22% of the disease liability in an
average patient.1 Although this is believed to be an
underestimate, it is also likely that there are nongenetic
influences, such as environmental exposure or stochas-
tic events. Genetics, however, has shown itself to be a
robust, tractable, and reliable method to understand
disease biology. Genetic understanding serves as a foun-
dation for succeeding functional studies and as a central
component of efforts to predict disease risk, onset, and
progression and to understand disease mechanisms in
individual patients. Without a reliable and complete
foundation of genetic understanding, we limit our abil-
ity to develop and deploy treatments.
A large number of risk loci and causative mutations
for PD have been identified; however, it is clear that the
majority of genetic risk remains to be found.1,2
Although much can be done with existing knowledge,
moving forward now to expand our genetic understanding
will be the foundation that will support the development
of a complete view of this network, providing an array of
potential therapeutic opportunities. Increasing genetic
information can only serve to improve our efforts to treat
disease.
Notably, our understanding of the genetic basis of
PD has thus far largely been centered on research in
individuals of northern European ancestry. Although
some genetic discoveries have been made outside these
populations, this work is the exception rather than the
norm and generally focuses on the identification of rare
mutations; little has been done in the identification of
more common genes or genetic risk discovery.3,4 Thus,
we do not know if our current understanding is gener-
alizable to the rest of the world and how the basis of
disease varies across populations. Although it is tempt-
ing to argue that the genetic basis for PD will generally
be the same across populations, we know that differ-
ences in genetic risk exist, and furthermore, there is evi-
dence to suggest that genetic forms of disease can
present differently across populations.3,5-8 This funda-
mental limitation of current research creates an inequi-
table situation for patients.
To facilitate the rapid expansion of our understanding
of the genetic architecture of PD, both in terms of the
depth and global context of this knowledge, we have cre-
ated the Global Parkinson’s Genetics Program (GP2;
www.gp2.org). GP2 is the first supported resource pro-
ject of the Aligning Science Across Parkinson’s (ASAP)
initiative, an audacious effort supporting PD research.9
GP2 is geared toward creating a worldwide collaborative
effort that will first dramatically accelerate the identifica-
tion of genetic contributors to disease and second estab-
lish a network of researchers who can best leverage this
understanding to research, diagnose, and treat PD
worldwide. Here we describe our mission, the path we
have proposed to achieve this, and the core principles of
data democratization, transparency, and diversity.
Mission and Underlying Principles
The mission of GP2 is to drive transformational pro-
gress in our understanding of the genetic architecture of
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PD and to serve as a useful and actionable resource for
the research and therapeutic development community.
To fully realize this mission, GP2 will need to engage
and mobilize a worldwide community of researchers
and participants, generate and analyze genetic data on
an extremely large scale, create an infrastructure that
removes obstacles to data access, and make data and
results accessible and useful to the broader commu-
nity (Fig. 1).
There are several underlying principles of GP2
that we believe are central to the overall success of our
work and the continued success of the research
community.
1. Diversification: We will leverage the power of diver-
sity across each dimension and in both researchers
and participants.
2. Democratization: We will ensure that the data, their
use, compute resources, and results are not only
available but also usefully accessible to the broader
research community. We will democratize GP2 and
the use of GP2 data through training for contribut-
ing sites to create clinical and data-analytical exper-
tise locally and regionally, growing our own and
collaborators’ capabilities.
3. Transparency and reproducibility: The collection,
data generation, data cleaning, and analysis will be
performed in an open manner. Methods, data, code,
and results will be available to the research commu-
nity to facilitate reproducibility, reduce redundancy,
and foster community involvement in and improve-
ment of approaches.
4. Collaboration and cooperation: We will promote a
high degree of collaboration and cooperation across
a global community. To be effective, this must be
centered on a shared vision, collective opportunities,
and responsibilities, ensuring that each member has
a voice in the organization.
5. Foundational, actionable resource generation: The
data and results we produce will form the founda-
tion of a wealth of scientific and clinical research;
therefore, they must be both easily available and in
a form that is useful for and interpretable by the
wider research community.
6. Safe, responsible data sharing: Data sharing with the
research community is key; however, this must be
done in a manner that ensures participant privacy
and is in line with local regulations. To do this, GP2
has a working group of experts examining compli-
ance at the level of the contributing institution and
country.
Deliverables and Path
Broadly, there are 2 scientific arms to GP2, one cen-
tered in genetically complex, typical PD and the other
in monogenic disease. Over the initial 5-year span of
the GP2 program, our path will lead us to a dramatic
increase in the number of known genes, disease-causing
mutations, and risk loci for both rare monogenic and
typical complex PD. Furthermore, this work will be
extended, for the first time at scale, to underrepresented
populations from around the world. We will generate
dense genetic data in more than 150,000 participants,
using a genotyping array specifically designed for this
purpose. We will also generate whole-genome sequence
data from more than 10,000 individuals to determine
the genetic cause in as yet unsolved monogenic cases
and to generate much needed reference data sets. Fur-
thermore, we will use long-read DNA sequencing to
support the analysis of structural and repeat variability
that is relatively resistant to interrogation using tradi-
tional genome sequencing methods. For the most part,
GP2 will use existing or ongoing patient and cohort
collections and will work with established PD consor-
tia; however, in some instances GP2 will support the
collection of additional patients, particularly from
underserved communities.
To ensure a functional and efficient structure, we cre-
ated a series of working groups and hubs that center on
achieving specific aims and priorities within GP2.
Although these groups have clear aims and deliverables,
they function as a continuum with shared mem-
bers (Fig. 2).
Complex Disease Genetics
The role of this group is to explore the genetic basis
of typical, apparently sporadic PD. The foundation of
this work will be the genotyping of 150,000 partici-
pants using an array designed by us specifically for this
purpose. The Neuro Booster Array is centered on the
backbone of the global diversity array (GDA; 1.8+ mil-
lion variants; https://www.illumina.com/products/by-
FIG. 1. The scientific outcomes and underlying structural priorities
of GP2. [Color figure can be viewed at wileyonlinelibrary.com]
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type/microarray-kits/infinium-global-diversity.html) but
also includes more than 95,000 custom content variants
that include neurological disease-oriented content and
population-specific boosters (article in preparation;
https://github.com/GP2code/Neuro_Booster_Array).
Broadly, we expect to generate data on 100,000
northern European ancestry individuals and more than
50,000 subjects from underrepresented populations
from around the world. We have established collabora-
tions to collect and assess cases of Black American, East
Asian, African, Indian, Caribbean and Central/South
American provenance. Our estimates of sample num-
bers are driven by a combination of resource availabil-
ity and pragmatism. However, we hope to significantly
increase the collection and genetic analysis of patients
from underrepresented groups well beyond these num-
bers, so 50,000 can be considered a lower bound. This
will depend on the availability of additional subjects
and how these cohorts are able to align with the GP2
general principles around data access and use. It is also
worth noting that the majority of GP2 genotyping will
be centered on persons with PD because abundant data
on controls already exist; however, some of our genetic
resources will be centered on generating genetic data in
controls, primarily for populations in which no such
data exist or for whom there are valuable PD related
data in these particular control samples (eg, bio-
marker data).
Data from underrepresented populations will be gen-
erated from a variety of sources. GP2 has already initi-
ated partnerships with academic research centers in the
United States to improve representation of Black Ameri-
cans within the project. Samples and data are being col-
lected from East Asia by the International Parkinson’s
Disease Genomics Consortium (IPDGC) East Asia
group, with efforts ongoing in Taiwan, Japan, South
Korea, and China. Likewise, IPDGC Africa has initi-
ated collaborations across Africa beginning with
patients from Nigeria, Egypt, Ethiopia, Ghana, Mali,
Tanzania, Senegal, South Africa, Sudan, and Zambia.
The Genetic Epidemiology of Parkinson’s disease
(GEoPD) Consortium has developed collaborations
across underrepresented populations from North
and sub-Saharan Africa, Australia, and Asia. The
FIG. 2. Organizational structure of GP2. [Color figure can be viewed at wileyonlinelibrary.com]
Movement Disorders, 2021 3
T H E G L O B A L P A R K I N S O N ’ S G E N E T I C S P R O G R A M
Luxembourgish-German Indian Alliance on Neurode-
generative Diseases and Therapeutics (Lux-GIANT) has
formed a collaborative group to investigate PD patients
across India.10 Last, the Latin American Research Con-
sortium on the Genetics of Parkinson’s Disease
(LARGE-PD) group is a fully active collaborative group
collecting and investigating patients from Argentina,
Brazil, Chile, Costa Rica, Colombia, Ecuador, Hondu-
ras, Mexico, Peru, Puerto Rico, Uruguay, and the West
Indies.11 As GP2 continues, there will be room to
expand to other countries and populations underserved
in our current research.
These data, collectively, will afford the opportunity
to rapidly detect novel genetic risk for PD. Critically,
the availability of similar data across ancestral groups
will allow an assessment of the varied genetic contribu-
tion in different ancestries, including the identification
of population-specific loci, an understanding of the dif-
ferences in the heritable component of disease between
groups, and the generation of population-specific
genetic risk profiles. Notably, these data collectively
provide the opportunity to refine association signals,
with transethnic fine-mapping.
A crucial step will be integration of clinical pheno-
type data. We know that there are diverse outcomes of
PD including the rate of motor and cognitive deteriora-
tion and medication side effects such as levodopa-
induced dyskinesias.12 We believe that these will be in
part genetically determined13,14 and that understanding
the associated genes and pathways will lead to new bio-
logical insights and importantly personalized treat-
ments. A barrier to this is the harmonization of data,
which is a major goal of the cohort integration group.
Monogenic Disease Genetics
Although modern genetic methods provide tools for
the rapid discovery of rare causal or high-risk muta-
tions, several barriers exist that limit the efficiency of
identifying novel causes of disease. First, multiplex fam-
ilies are overall rare and dispersed. Second, the genera-
tion and analysis of genetic data are specialized and
expensive. Third, existing genetic data are not harmo-
nized and often not available for sharing. And, fourth,
penetrance is reduced in dominantly inherited forms
and, although high in recessive forms, age dependent.
The latter results in frequent absence of the most prom-
inent red flag for the occurrence of a monogenic form
of PD, that is, positive family history, so that a signifi-
cant proportion of patients miss out on genetic testing
and research because they are not deemed good candi-
dates. Collectively, this means that finding segregating
mutations, or mutations in the same putative novel
gene, is difficult; this, in turn, has resulted in the publi-
cation of a growing number of potentially disease-
associated mutations that are preliminary and can be
quite misleading or confusing to the field. Importantly,
and unlike findings from complex genetic studies of PD,
these putative new monogenic causes are often readily
implemented in PD gene panels for diagnostic testing
by genetic testing companies, posing an additional chal-
lenge to patients, unaffected carriers, genetic coun-
selors, and physicians in terms of interpretation of the
ensuing test results.
The monogenic disease arm of GP2 aims to address
these obstacles and thereby create an efficient infra-
structure to accelerate the identification of novel genetic
causes of apparently monogenic PD. Leveraging the
above-described global network of researchers contrib-
uting patient samples to Neuro Booster Array
genotyping and including already-existing resources
from the monogenic field, such as IPDGC,15 the
GEoPD, and the Michael J. Fox Foundation Global
Genetic Parkinson’s Disease Study Group,16 the mono-
genic arm will collect >5000 patients and families in
whom a monogenic cause may be suspected. Particular
emphasis will be placed on families from underrepre-
sented populations. All currently known PD genes have
been found in various populations around the globe,
however, some occur at highly variable and
population-specific frequencies, the most striking exam-
ples being the p.G2019S mutation in the LRRK2 gene17
and GBA mutations including p.N370S18 and p.
K198E.19 In addition, it is conceivable that population-
specific hereditary forms of PD may exist, as exempli-
fied by X-linked dystonia-parkinsonism, a condition
exclusively present in patients of Filipino ancestry,20 for
which the underlying genetic cause has been identified
as well as genetic age-at-onset modifiers.21-23 This con-
dition has served as an important model for basal gang-
lia disease.24,25
The monogenic arm will collect families, singleton
cases, and patient-parent trios and prioritize these for
whole genome sequency or long-read DNA sequencing
based on a number of different criteria: family history
and availability of samples from several affected (and
unaffected) family members, age at onset, ethnicity
(with a focus on underrepresented populations), and
level of available genetic prescreening. Importantly, all
patients enrolled in the monogenic arm of the project
will also undergo Neuro Booster Array genotyping,
which, based on its PD-related custom content, will
result in the identification of a sizable number of
patients with mutations in known PD genes. Assuming
that an average of 10%–15% of all PD patients carry
a mutation in a known PD gene (3%–5%) or a high-
risk variant in GBA (8%–10%),26 we estimate a total
of 15,000 monogenic or high-risk variant carriers to
be detected in the total GP2 sample set. It is at this
important interface, where the complex genetic and
monogenic arms will interact most closely: although the
complex genetics arm will identify carriers of known
4 Movement Disorders, 2021
G P 2 I N V E S T I G A T O R S
PD-causing mutations that can then be enrolled in vari-
ous additional investigations, such as genetic modifier
studies of age at onset, the monogenic hub will contact
all submitters of patients to the monogenic hub to also
enroll patient and control cohorts into the complex
genetics hub. This interplay will create unprecedented
opportunities not only for the discovery of novel
genetic causes of PD but also for a better understanding
of the known genetic forms of PD.
The Democratization of Data
Resources
Over the last 15 years, the genetics field has made
great strides toward making data available to the
research community. However, barriers still exist. Data
are typically highly dispersed across silos/portals, there
is often considerable administrative burden for data
access especially when accessing multiple data sets, and
data use agreements can be restrictive. In addition, the
analytical expertise to interpret results or analyze data
can be high, and the cost of data analysis plus curation
can be prohibitive. A key stated outcome of GP2 is the
generation of data and analyses that can be readily
accessed and interpreted by the broad research commu-
nity. To achieve this, we are taking several steps to con-
solidate data in one place and provide all analysis
scripts with the necessary context in GitHub (https://
github.com/GP2code), a public domain.
We will place as much information as timely and
responsibly possible in the public domain, without
requiring an extensive data-use agreement. Although
the protection of participant’s data must be a priority, a
large number of analyses only require summary results,
and many of these can be shared publicly. Deidentified
participant-level data will be stored securely; however,
we will only require a single data-use agreement to
access these cohorts, streamlining the data access pro-
cess. An essential step in the onboarding process for
collaborating cohorts is the consent and regulatory
review process performed by the Operations and
Compliance Working Group. This group works with
investigators and institutional officials to surface any
cohort-specific requirements for international data shar-
ing. Our ability to comply with these regulations while
maintaining our philosophy of data accessibility and
open science are taken into account when deciding if
we would like to move forward with integrating the
cohort into GP2.
We will follow a model in which researchers analyze
data in place, rather than downloading data to local
computers. This approach offers several advantages. It
means that we can reduce redundancies by capturing
standard quality control and analyses and sharing these
as a common path. It means we can create collaborative
and training opportunities and resources by working
across a common, shared workspace. In GP2, we can
be both standardized and transparent in our analyses,
which can be easily shared with the research commu-
nity, allowing independent testing, additive analyses,
and crowd-sourced improvements to workflows. This
approach democratizes the data, tools, and infrastruc-
ture, allowing individuals with the skill set but without
the computing resources to access and analyze these
data. The model of analysts coming to the data, rather
than vice versa, is one being increasingly used or pro-
moted by major national and global genetics and geno-
mics initiatives such as the International Complex
Disease Alliance (see white paper at https://www.icda.
bio/) and the AllOfUs initiative (https://allofus.nih.gov/
). To achieve these aims, our current model is centered
around Terra (https://terra.bio/) with other platform
options possible soon.
Terra is a cloud-based, scalable platform developed
and actively maintained by the Broad Institute (https://
www.broadinstitute.org/) specifically for biomedical
research. Terra supports direct access and analysis of
data, eliminating the need for data download. Terra
workflows allow researchers to perform whole analyti-
cal pipelines, such as aligning sequence data per sample
and joint calling across populations and, combined
with notebooks, follow an intuitive structure and inter-
active analysis. Thus, by sharing notebooks and
workspaces Terra makes collaboration easy and trans-
parent. This allows researchers to easily use and repro-
duce workflows, reducing redundancy and maximizing
transparency.
Training and Networking
It is not enough to just make data available to the
wider PD research community. A key part of GP2 is to
develop training opportunities that will benefit clini-
cians and researchers around the world so that they
may pursue their own questions using GP2 data.
We recognize that a significant barrier to those
wishing to work with genetic data is expertise. These
training opportunities aim to establish broad,
foundation-level knowledge in genetics, bioinformatics,
medical statistics, and molecular biology through a
suite of new web-based materials. Our program of
web-based training has been brought into sharp focus
by the COVID-19 pandemic, and we have accelerated
our efforts to deliver educational material despite travel
restrictions. This has had the benefit of making these
training opportunities more readily accessible to investi-
gators from around the world. We also aim to support
clinical training opportunities in regions that would
benefit most from this. Our hope is that these resources
will increase the efficiency of and participation in GP2,
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particularly for those where such training is typically
difficult to access.
For individuals who demonstrate exceptional drive
and talent, whatever their background, we will support
a range of individual formal training opportunities in
the form of taught courses (such as master’s degrees),
customized training visits at centers of excellence, and
full PhD studentships. We are committed to serving the
needs of clinicians and researchers who have been
underrepresented so far in research, and we will enable
research training opportunities and build sustainable
partnerships through a network of GP2 collaborators.
Promoting Diversity
We believe that a critical component of expanding
research to underserved and underrepresented
populations is ensuring ownership of local studies by
local researchers, an active voice and role in the global
study, and training, development, and other infrastruc-
ture support for local researchers to build on their
expertise.
As noted above, we aim to support the development
of local, clinical, and analytical expertise. Further, all
data are returned to contributing investigators immedi-
ately on completion of harmonization and quality con-
trol. Using a shared compute space, the individual
investigator can access the processing and quality con-
trol workspaces that have been used to generate these
data. Local investigators can also use the skills trans-
ferred from training to perform collaborative analysis
in GP2-supported cloud computing, removing the bar-
rier of providing their own infrastructure. GP2 also
aims to provide several layers of analytical support
beyond training. We have a data analysis core that not
only serves to perform study-wide analyses but also to
support members in the form of direct analytical ser-
vices, partners in one-on-one training, and by providing
a data concierge service.
Uses of These Data
The work planned for GP2 will provide foundational
data and fundamental insights for PD research. We
believe that this work touches almost every aspect of
the path from basic biological understanding to thera-
peutic deployment. Most obviously, the work from
GP2 will lead to a significant increase in the proportion
of the known heritable component of disease, identify-
ing novel risk factors, mutations, and disease-linked
genes.2 This will improve the genetic component of
multimodal risk prediction models and will provide us
with greater power to determine whether genetic sub-
types of the common disease are present.
Based on prior experience, the expansion of efforts
into traditionally underrepresented populations will
also lead to the identification of new loci that are either
absent or of weaker effect in the northern European
population.3,5,6 These data will allow us to determine
whether heritability differs substantially across ances-
tral groups and to construct ancestry-specific risk pro-
files. It will provide insight into the genetic basis of
differences in disease presentation and course, as well
as highlighting which groups may be particularly suited
to a distinct etiologic-based therapeutic approach. Fur-
ther, these data allow transethnic fine-mapping to be
used to reduce the critical intervals in which functional
risk alleles reside and to identify the functional
effector gene.
Beyond risk, GP2 provides the opportunity to exam-
ine the genetic basis of variability in disease. Age at
onset, progression, and the range of symptoms and
comorbidities are each amenable to genetic discovery.
Perhaps more importantly, this work paves the way for
the creation of individual risk profiles for onset and tra-
jectories of disease.
Combining complex genetic approaches with data
produced in monogenic cases also allows the identifica-
tion of genetic modifiers of disease penetrance.26,27 Fur-
thermore, these data suggest that such work may reveal
differential effects of the same risk loci in primarily
monogenic and complex disease, a potential functional
basis for etiologic differences or at least different etio-
logic weights between patients. This area is of stated
interest to our colleagues in industry who are looking
for potential modifiers of the disease process.
Broad Applicability
There are a wide variety of opportunities provided by
the GP2 study that are not part of its most immediate
scope, and there is significant potential for additional
work made possible through the generation of GP2
data. Our partnership with the PPMI study (https://
www.ppmi-info.org/) enables the use of genetics in bio-
marker development work, integrating genetics in mul-
timodal disease predictions, an examination of the
influence of ancestry on biomarkers, and the use of
genetics to improve biomarker readouts by adjusting
for genetic influence unrelated to disease.
Like PPMI, many studies have collected additional
data that can be analyzed with genetics. The availability
of imaging and neuropathology data provides an
opportunity to understand the genetic basis of variance
in these measures and may offer insights on disease sub-
typing. Combining data from largely unbiased methods
such as transcriptomics, epigenomics, metabolomics,
and proteomics with genetics provides the opportunity
to map quantitative trait loci in both health and
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disease, an approach that has been used to understand
basic etiology and improve biomarker accuracy.
The sponsorship of GP2 in collecting samples from
underrepresented populations also opens up the oppor-
tunity to perform ancillary studies in these groups. At
the most basic level this may include simple phenotypic
characterization of patients from countries or ancestral
groups in which little has previously been done. It can
also include work on attitudes and perspectives on dis-
ease and the use of genetics.
We believe these opportunities and myriad others in
the spaces of environment, epidemiology, epigenetics,
and beyond can be prioritized for further research. Our
aim in GP2 is not to create an organization that tackles
each of these, but rather to create a structure around
which such studies can be organized. Our hope is that
individual investigators within the GP2 network will
propose new lines of investigation and form alliances
and collaborations with other investigators to explore
these questions. GP2 and our collective data and struc-
ture can serve as an initiator for such work.
Cellular Context and Function
The identification of novel PD-linked gene mutations
and loci will add insight into the underlying basis and
biology of disease. Integrating these results with other
genomic data can provide compelling evidence on the
cellular context of genetic risk, a key step in ensuring
the relevance of modeling efforts.1,28,29 Likewise, the
more genetic information we possess, the more com-
plete is the picture we can construct of the pathogenesis
of disease. ASAP has supported a series of ambitious
projects within the Collaborative Research Network
(https://parkinsonsroadmap.org/research-network/)
with a major focus on work to determine the biology of
PD-associated genetics. GP2 will be a foundational
resource for these studies. In the relatively short time
that we have reliably been able to identify genetic risk
factors at scale, the translation to mechanistic under-
standing has been challenging. However, recent
advances, particularly in the space of single-cell geno-
mics, promise to elucidate the cellular context, effector
gene, and immediate biological effect. Once defined, the
cellular context and disease-relevant effect on expres-
sion can be used in traditional reductionist and systems
approaches to define disease pathways and networks.
Regardless of the path taken, a fundamental under-
standing of the breadth and depth of genetic influence
in PD will enhance our ability to understand the disease
process.
Informing Trial Design
GP2’s work can afford us insights into the idea of
mechanistic subsetting of disease, whether there are
many distinct networks involved in the disease process
and the distribution of these mechanisms across a typi-
cal PD population. Critically, if we find enriched or
divergent mechanisms in subsets of patients, it will be
important to match patients with mechanistic personal-
ized therapeutics. This is, in essence, an extension of
the rational idea of testing (for example) LRRK2 kinase
inhibitors initially in LRRK2 mutation-positive cases.
Further, GP2 will improve prediction of disease risk
and progression. This information will serve to facili-
tate improved clinical trial design, supporting trials in
early (even preclinical) patients and adjusting outcomes
based on individualized predictions of progression.
The Future
As discussed above, there are a large number of
potential projects and opportunities associated with the
GP2 data and collaborative framework. We are clearly
at the beginning of our journey, but it is certainly diffi-
cult to resist the temptation to speculate on what priori-
ties and opportunities may emerge as we continue.
The results of our current work inform the course
forward. The efforts of the monogenic group are
already providing a clearer understanding of what is
left to be found. Can we identify modifiers to mono-
genic disease? How close are we to identifying the
majority of these factors? What critical features remain
to determine which mutation carriers will express dis-
ease, and when? Likewise, data from the complex
genetics group will address similar questions. We will
be better able to understand when we have reached bio-
logical saturation in common risk loci — the point at
which newly identified loci are failing to add new
insight into disease biology — perhaps an appropriate
stopping point for genome-wide association studies. We
will also have a good idea of whether scaling up our
sequencing efforts in complex disease makes sense —
do we see significant additional discoveries or resolu-
tion using this method over genotyping?
At the simplest level, scale is immediately compelling,
and it is apparent even now that it would be particu-
larly important to scale up our work in underrepre-
sented groups. We know our current efforts in
underrepresented groups represent a significant com-
mitment and a major step forward for the field. How-
ever, they are just a start. It will be important to
capitalize on this momentum and continue to invest in
research within and by underserved communities so
that we can realize the potential of this work.
Last, we should also consider the next immediate
steps after genetic discovery. In many ways genetics has
evolved into a commodity. We have a clear path for-
ward and broad consensus on the road to take. This is
also becoming true for the next immediate steps to
translate from genetic maps to mechanism, and there
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may be some advantage to GP2 tackling some of these
problems, particularly around the creation of resources
to make this translation efficient. However, regardless
of how we get to these next steps, we believe that GP2
will serve as the starting point on this journey and a
foundation for the global PD research community. We
are excited about the progress we have made so far and
thrilled to be making this journey with our partners.
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Global Parkinson’s Genetics Program Members
Name Institute
Ai Huey Tan Division of Neurology, Department of Medicine and the Mah Pooi Soo & Tan Chin Nam Centre for Parkinson’s & Related Disorders,
Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
Alastair Noyce Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen
Mary University, London, United Kingdom
Alejandro Martinez
Carrasco
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
Alexis Brice Institute for Brain and Spinal Cord, Paris, France
Alyssa Reimer The Michael J. Fox Foundation for Parkinson’s Research, New York, NY, USA
Anastasia Illarionova German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany
Andrew Singleton Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD
Artur Schumacher-
Schuh
Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Benjamin Stecher Independent patient advocate and consultant
Bernadette Siddiqi The Michael J. Fox Foundation for Parkinson’s Research, New York, NY
Bradford Casey The Michael J. Fox Foundation for Parkinson’s Research, New York, NY
Brian Fiske The Michael J. Fox Foundation for Parkinson’s Research, New York, NY
Caroline Pantazis Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD
Christine Klein Institute of Neurogenetics, University of Luebeck, Luebeck, Germany
Claire Bale Parkinsons UK, London, UK
Claire Wegel Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN
Cornelis Blauwendraat Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD
Dan Vitale Data Tecnica International, Glen Echo, MD
Dena Hernandez Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD
Ekemini Riley Aligning Science Across Parkinson’s, Chevy Chase, MD
Emily Fisher Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen
Mary University, London, UK
Enza Maria Valente Department of Molecular Medicine, University of Pavia and IRCCS Mondino Foundation, Pavia, Italy
Eva Juliane Vollstedt Institute of Neurogenetics, University of Luebeck, Luebeck, Germany
Faraz Faghri Data Tecnica International, Glen Echo, MD
Hampton Leonard Data Tecnica International, Glen Echo, MD
Hirotaka Iwaki Data Tecnica International, Glen Echo, MD
Huw Morris Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
Ignacio Juan Keller
Sarmiento
Northwestern University, Feinberg School of Medicine, Department of Neurology, Chicago, IL
Ignacio Mata Genomic Medicine Institute, Cleveland Clinic & Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western
Reserve University, Cleveland, OH
Jeff Kim Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD
John Hardy Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
Kaileigh Murphy The Michael J. Fox Foundation for Parkinson’s Research, New York, NY
Katja Lohmann Institute of Neurogenetics, University of Luebeck, Luebeck, Germany
Ken Marek The Michael J. Fox Foundation for Parkinson’s Research, New York, NY
Kin Mok UK Dementia Research Institute at UCL and Department of Neurodegenerative Disease, UCL Institute of Neurology, University
College London, London, UK
Kishore Kumar Molecular Medicine Laboratory, Concord Hospital, University of Sydney, Garvan Institute, Sydney, Australia
Lara Lange Institute of Neurogenetics, University of Luebeck, Luebeck, Germany
Maggie Kuhl The Michael J. Fox Foundation for Parkinson’s Research, New York, NY
Manu Sharma Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen,
Germany
Manuela Tan Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
Mary Makarious Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD
Michelle Durborow The Michael J. Fox Foundation for Parkinson’s Research, New York, NY
Micol Avenali Department of Brain and Behavioural Sciences, University of Pavia and IRCCS Mondino Foundation, Pavia, Italy
Mie Rizig Department of Molecular Neuroscience, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London,
UK
Mike Nalls Data Tecnica International, Glen Echo, MD
Niccolo Mencacci Northwestern University, Feinberg School of Medicine, Department of Neurology, Chicago, IL
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Appendix Continued
Name Institute
Nicholas Wood Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
Nigel Williams MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff
University, Cardiff, UK
Njideka Okubadejo Neurology Unit, Department of Medicine, College of Medicine, University of Lagos, Idi Araba, Lagos State, Nigeria
Olaitan Okunoye Department of Movement and Clinical Neurosciences, Queen Square Institute of Neurology, University College London, London, UK
Patrick Lewis Comparative Biomedical Sciences, Royal Veterinary College, London, UK
Peter Heutink German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany
Prashanth LK Parkinson’s Disease & Movement Disorders Clinic, Vikram Hospitals, Bangalore, Karnataka, India
Rejko Kruger Luxembourg Institute of Health (LIH), Strassen, Luxembourg; Luxembourg Centre for Systems Biomedicine (LCSB), University of
Luxembourg, Esch-sur-Alzette, Luxembourg; Centre Hospitalier de Luxembourg (CHL), Luxembourg
Roopa Rajan All India Institute of Medical Sciences, New Delhi, India- 110029
Ruqaya Murtadha Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD
Sabina Adams Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen
Mary University, London, UK
Sara Bandres-Ciga Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD
Schuyler Fox The Michael J. Fox Foundation for Parkinson’s Research, New York, NY
Shen-Yang Lim Division of Neurology, Department of Medicine; and The Mah Pooi Soo & Tan Chin Nam Centre for Parkinson’s & Related
Disorders, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
Simon Stott Cure Parkinsons Trust, London, UK
Soraya Bardien Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town,
South Africa
Tatiana Foroud Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN
Thomas Gasser Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
Todd Sherer The Michael J. Fox Foundation for Parkinson’s Research, New York, NY
Yeajin Song Data Tecnica International, Glen Echo, MD
Zih-Hua Fang German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany
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